Q17QH7
PR
Gene name |
TFPT |
Protein name |
TCF3 fusion partner homolog |
Names |
|
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:506610 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q17QH7
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q17QH7-F1 | Predicted | AlphaFoldDB |
124 variants for Q17QH7
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs464346256 | 3 | L>M | No | EVA | |
| rs464764553 | 12 | A>D | No | EVA | |
| rs464764553 | 12 | A>G | No | EVA | |
| rs433387413 | 13 | V>G | No | EVA | |
| rs456814618 | 14 | G>A | No | EVA | |
| rs476865047 | 15 | F>L | No | EVA | |
| rs435899090 | 16 | E>G | No | EVA | |
| rs455675463 | 17 | E>G | No | EVA | |
| rs441294340 | 18 | F>C | No | EVA | |
| rs472591003 | 18 | F>V | No | EVA | |
| rs458196602 | 19 | S>P | No | EVA | |
| rs471590283 | 20 | A>T | No | EVA | |
| rs443350155 | 21 | P>S | No | EVA | |
| rs459337569 | 25 | E>A | No | EVA | |
| rs459337569 | 25 | E>G | No | EVA | |
| rs479503481 | 26 | L>V | No | EVA | |
| rs444908889 | 27 | A>E | No | EVA | |
| rs481935082 | 30 | P>Q | No | EVA | |
| rs435837700 | 35 | H>D | No | EVA | |
| rs456011858 | 36 | I>L | No | EVA | |
| rs466160868 | 36 | I>M | No | EVA | |
| rs434812354 | 40 | E>A | No | EVA | |
| rs451693393 | 41 | L>P | No | EVA | |
| rs471677358 | 42 | E>Q | No | EVA | |
| rs443692191 | 45 | V>A | No | EVA | |
| rs473842155 | 47 | F>C | No | EVA | |
| rs456930560 | 47 | F>L | No | EVA | |
| rs456930560 | 47 | F>V | No | EVA | |
| rs459615975 | 49 | S>T | No | EVA | |
| rs438349341 | 55 | S>C | No | EVA | |
| rs438349341 | 55 | S>Y | No | EVA | |
| rs481871381 | 58 | R>P | No | EVA | |
| rs480842128 | 63 | E>D | No | EVA | |
| rs449547264 | 66 | A>G | No | EVA | |
| rs466388330 | 68 | R>G | No | EVA | |
| rs435093809 | 68 | R>L | No | EVA | |
| rs465207136 | 70 | R>L | No | EVA | |
| rs457319000 | 71 | R>P | No | EVA | |
| rs473782747 | 73 | R>G | No | EVA | |
| rs473257779 | 81 | K>N | No | EVA | |
| rs458490887 | 82 | Y>* | No | EVA | |
| rs438691737 | 82 | Y>D | No | EVA | |
| rs481858946 | 83 | Q>P | No | EVA | |
| rs481126577 | 89 | C>G | No | EVA | |
| rs449363710 | 91 | E>D | No | EVA | |
| rs459952590 | 92 | I>N | No | EVA | |
| rs478430935 | 95 | V>L | No | EVA | |
| rs470442675 | 99 | V>G | No | EVA | |
| rs449142327 | 101 | N>K | No | EVA | |
| rs466223818 | 102 | R>K | No | EVA | |
| rs434844086 | 103 | L>V | No | EVA | |
| rs451716474 | 104 | H>D | No | EVA | |
| rs471394112 | 104 | H>P | No | EVA | |
| rs436924199 | 105 | Q>P | No | EVA | |
| rs457152876 | 106 | V>A | No | EVA | |
| rs457152876 | 106 | V>G | No | EVA | |
| rs459269432 | 108 | R>K | No | EVA | |
| rs473082895 | 109 | I>K | No | EVA | |
| rs438495865 | 110 | T>N | No | EVA | |
| rs458667770 | 111 | R>L | No | EVA | |
| rs458667770 | 111 | R>P | No | EVA | |
| rs458667770 | 111 | R>Q | No | EVA | |
| rs481933227 | 112 | R>G | No | EVA | |
| rs463970507 | 115 | Q>P | No | EVA | |
| rs444703838 | 123 | V>G | No | EVA | |
| rs476105083 | 123 | V>L | No | EVA | |
| rs461345078 | 125 | D>E | No | EVA | |
| rs475058230 | 127 | Y>* | No | EVA | |
| rs440517110 | 130 | D>E | No | EVA | |
| rs133952920 | 131 | Y>S | No | EVA | |
| rs460600314 | 133 | S>P | No | EVA | |
| rs477518075 | 140 | L>R | No | EVA | |
| rs439772097 | 142 | D>Y | No | EVA | |
| rs462747676 | 148 | T>P | No | EVA | |
| rs441891597 | 152 | T>P | No | EVA | |
| rs721464649 | 154 | G>S | No | EVA | |
| rs447158061 | 157 | E>D | No | EVA | |
| rs526275105 | 197 | R>C | No | EVA | |
| rs451397412 | 213 | I>L | No | EVA | |
| rs471631280 | 213 | I>T | No | EVA | |
| rs443552529 | 214 | K>Q | No | EVA | |
| rs473855611 | 215 | V>G | No | EVA | |
| rs463311958 | 215 | V>I | No | EVA | |
| rs442476934 | 218 | D>A | No | EVA | |
| rs459406704 | 219 | F>L | No | EVA | |
| rs458340425 | 222 | E>* | No | EVA | |
| rs478539937 | 223 | A>S | No | EVA | |
| rs450410864 | 224 | D>A | No | EVA | |
| rs470149748 | 224 | D>E | No | EVA | |
| rs450410864 | 224 | D>G | No | EVA | |
| rs449216326 | 225 | E>A | No | EVA | |
| rs449216326 | 225 | E>G | No | EVA | |
| rs435614937 | 225 | E>Q | No | EVA | |
| rs466052432 | 228 | D>A | No | EVA | |
| rs466052432 | 228 | D>G | No | EVA | |
| rs434868410 | 229 | S>P | No | EVA | |
| rs451383097 | 230 | S>I | No | EVA | |
| rs451383097 | 230 | S>N | No | EVA | |
| rs471637225 | 230 | S>R | No | EVA | |
| rs437077085 | 231 | W>S | No | EVA | |
| rs457275322 | 232 | V>A | No | EVA | |
| rs457275322 | 232 | V>G | No | EVA | |
| rs442396332 | 233 | S>A | No | EVA | |
| rs452949658 | 233 | S>Y | No | EVA | |
| rs438551072 | 234 | R>L | No | EVA | |
| rs478497775 | 236 | P>Q | No | EVA | |
| rs464020409 | 237 | D>A | No | EVA | |
| rs464020409 | 237 | D>G | No | EVA | |
| rs443882024 | 237 | D>Y | No | EVA | |
| rs449165486 | 238 | K>N | No | EVA | |
| rs481006849 | 238 | K>R | No | EVA | |
| rs479696538 | 240 | L>R | No | EVA | |
| rs465114868 | 241 | P>T | No | EVA | |
| rs436949651 | 242 | Y>C | No | EVA | |
| rs436949651 | 242 | Y>S | No | EVA | |
| rs482472182 | 244 | T>P | No | EVA | |
| rs467663101 | 245 | L>P | No | EVA | |
| rs473017915 | 248 | P>R | No | EVA | |
| rs382128380 | 249 | P>A | No | EVA | |
| rs446350019 | 249 | P>R | No | EVA | |
| rs438512117 | 250 | F>L | No | EVA | |
| rs475514107 | 251 | D>V | No | EVA | |
| rs452217515 | 251 | D>Y | No | EVA | |
| rs463940832 | 252 | D>Y | No | EVA |
No associated diseases with Q17QH7
No regional properties for Q17QH7
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| No domain, repeats, and functional sites for Q17QH7 | |||
4 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| Ino80 complex | A multisubunit protein complex that contains the Ino80p ATPase; exhibits chromatin remodeling activity. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
2 GO annotations of molecular function
| Name | Definition |
|---|---|
| DNA binding | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). |
| protein kinase binding | Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. |
14 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| apoptotic signaling pathway | The series of molecular signals which triggers the apoptotic death of a cell. The pathway starts with reception of a signal, and ends when the execution phase of apoptosis is triggered. |
| chromatin remodeling | A dynamic process of chromatin reorganization resulting in changes to chromatin structure. These changes allow DNA metabolic processes such as transcriptional regulation, DNA recombination, DNA repair, and DNA replication. |
| DNA recombination | Any process in which a new genotype is formed by reassortment of genes resulting in gene combinations different from those that were present in the parents. In eukaryotes genetic recombination can occur by chromosome assortment, intrachromosomal recombination, or nonreciprocal interchromosomal recombination. Interchromosomal recombination occurs by crossing over. In bacteria it may occur by genetic transformation, conjugation, transduction, or F-duction. |
| DNA repair | The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway. |
| positive regulation of apoptotic process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. |
| positive regulation of DNA repair | Any process that activates or increases the frequency, rate or extent of DNA repair. |
| positive regulation of DNA-templated transcription | Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription. |
| positive regulation of telomere maintenance in response to DNA damage | Any process that activates or increases the frequency, rate or extent of telomere maintenance in response to DNA damage. |
| regulation of cell cycle | Any process that modulates the rate or extent of progression through the cell cycle. |
| regulation of DNA replication | Any process that modulates the frequency, rate or extent of DNA replication. |
| regulation of DNA strand elongation | Any process that modulates the rate, frequency or extent of DNA strand elongation. DNA strand elongation is the DNA metabolic process in which an existing DNA strand is extended by activities including the addition of nucleotides to the 3' end of the strand. |
| regulation of embryonic development | Any process that modulates the frequency, rate or extent of embryonic development. |
| telomere maintenance | Any process that contributes to the maintenance of proper telomeric length and structure by affecting and monitoring the activity of telomeric proteins, the length of telomeric DNA and the replication and repair of the DNA. These processes includes those that shorten, lengthen, replicate and repair the telomeric DNA sequences. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MELEQREGTM | AAVGFEEFSA | PPGSELALPP | LFGGHILESE | LETEVEFVSG | GLGGSGLRER |
| 70 | 80 | 90 | 100 | 110 | 120 |
| DEEEEAARGR | RRRQRELNRR | KYQALGRRCR | EIEQVNERVL | NRLHQVQRIT | RRLQQERRFL |
| 130 | 140 | 150 | 160 | 170 | 180 |
| MRVLDSYGDD | YRSSQFTIVL | EDEGSQGTDA | PTPGNAENEP | PDKEGLSPPR | RTPAPPEPGS |
| 190 | 200 | 210 | 220 | 230 | 240 |
| PAPGEGPSGR | KRRRAPRDTR | RVGAALTPEL | APIKVEEDFG | FEADEALDSS | WVSRGPDKLL |
| 250 | |||||
| PYPTLASPPF | D |